Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enfortumab vedotin - Astellas Pharma/Seagen

Next Previous
X
Search
Drug Profile

Enfortumab vedotin - Astellas Pharma/Seagen

Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin-ejfv; PADCEV

Latest Information Update: 29 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agensys; Seattle Genetics
  • Developer Astellas Pharma; Astellas Pharma Global Development; Merck & Co; Seagen; Utah State University
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase III Bladder cancer
  • Phase II Prostate cancer; Solid tumours

Most Recent Events

  • 28 Aug 2024 Launched for Urogenital cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Sweden (IV)
  • 28 Aug 2024 Registered for Urogenital cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Liechtenstein, Norway, Iceland (IV)
  • 28 Aug 2024 Registered for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in European Union (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top